We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+6.94%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$54.2B
AUM Growth
+$30.1B
(+125%)
Cap. Flow
+$28.6B
Cap. Flow
% of AUM
52.81%
Top 10 Holdings %
Top 10 Hldgs %
15.56%
Holding
4,600
New
1,635
Increased
1,281
Reduced
635
Closed
782
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.08B |
| 2 |
Amazon
AMZN
|
+$1B |
| 3 |
Meta Platforms (Facebook)
META
|
+$844M |
| 4 |
Apple
AAPL
|
+$842M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$725M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Accenture
ACN
|
+$192M |
| 2 |
West Pharmaceutical
WST
|
+$107M |
| 3 |
Advanced Micro Devices
AMD
|
+$97.2M |
| 4 |
Bio-Rad Laboratories Class A
BIO
|
+$79.3M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$79.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.77% |
| 2 | Healthcare | 17.47% |
| 3 | Financials | 15.58% |
| 4 | Consumer Discretionary | 12.3% |
| 5 | Communication Services | 8.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3376
Relay Therapeutics
RLAY
$4.06B
| $77K | ﹤0.01% |
2,499
-17,231
| -87% | -$545K |
|
|
CSTR
3377
DELISTED
CapStar Financial Holdings, Inc
CSTR
| $77K | ﹤0.01% |
+3,622
| New | +$77.8K |
|
3378
International Seaways
INSW
$4.49B
| $76K | ﹤0.01% |
+5,158
| New | +$85.4K |
|
3379
Invesco Pharmaceuticals ETF
PJP
$439M
| $75K | ﹤0.01% |
+922
| New | +$72.9K |
|
|
ENVXW
3380
CALL
DELISTED
Enovix Corporation Warrant
ENVXW
| $75K | ﹤0.01% |
+2,733
| New | +$44.5K |
|
3381
Urban One Class A
UONE
$22.7M
| $74K | ﹤0.01% |
+1,582
| New | +$107K |
|
|
MITSY
3382
DELISTED
MITSUI & CO LTD ADR (US)
MITSY
| $74K | ﹤0.01% |
+154
| New | +$74K |
|
3383
Annexon
ANNX
$841M
| $73K | ﹤0.01% |
+6,260
| New | +$101K |
|
3384
4D Molecular Therapeutics
FDMT
$543M
| $73K | ﹤0.01% |
+3,317
| New | +$81.3K |
|
3385
Kamada
KMDA
$403M
| $73K | ﹤0.01% |
+11,046
| New | +$65.8K |
|
3386
Real Brokerage
REAX
$384M
| $73K | ﹤0.01% |
+19,568
| New | +$55.9K |
|
|
CCF
3387
DELISTED
Chase Corporation
CCF
| $73K | ﹤0.01% |
+733
| New | +$75K |
|
3388
Immunovant
IMVT
$8.23B
| $71K | ﹤0.01% |
8,316
-64,506
| -89% | -$533K |
|
3389
PEDEVCO
PED
$153M
| $71K | ﹤0.01% |
+3,352
| New | +$93.1K |
|
3390
SPS Commerce
SPSC
$2.41B
| $71K | ﹤0.01% |
+497
| New | +$74.5K |
|
|
DM
3391
DELISTED
Desktop Metal, Inc.
DM
| $71K | ﹤0.01% |
+1,434
| New | +$96.5K |
|
|
MIXT
3392
DELISTED
MIX TELEMATICS LIMITED
MIXT
| $71K | ﹤0.01% |
5,572
-25,824
| -82% | -$314K |
|
3393
AYTU BioPharma
AYTU
$22.1M
| $70K | ﹤0.01% |
+2,600
| New | +$112K |
|
|
CADE
3394
DELISTED
Cadence Bank
CADE
| $70K | ﹤0.01% |
+2,402
| New | +$72.6K |
|
3395
Escalade
ESCA
$262M
| $70K | ﹤0.01% |
+4,369
| New | +$78.8K |
|
3396
Mustang Bio
MBIO
$4.24M
| $70K | ﹤0.01% |
+57
| New | +$92K |
|
3397
RxSight
RXST
$233M
| $68K | ﹤0.01% |
6,034
-11,671
| -66% | -$140K |
|
3398
Tango Therapeutics
TNGX
$4.35B
| $68K | ﹤0.01% |
+6,269
| New | +$75.4K |
|
3399
Bassett Furniture
BSET
$169M
| $67K | ﹤0.01% |
4,014
-6,276
| -61% | -$109K |
|
3400
CALL
Freeport-McMoran
FCX
$90.2B
| $67K | ﹤0.01% |
1,600
+600
| +60% | +$22.8K |
|
Similar funds
Marshall Wace's Q4 2021 Portfolio in Review
As of Q4 2021, Marshall Wace held 4,600 positions worth $54.2B, up 125% from $24.1B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Marshall Wace deployed $28.6B of net new capital in Q4 2021, opening 1,635 new positions and adding to 1,281 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 1,140,732 shares worth $542M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 14% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Accenture, an estimated $192M trimmed.
- Marshall Wace's largest Q4 2021 buy was State Street SPDR S&P 500 ETF Trust: 1,140,732 shares worth $542M.
- Marshall Wace added most to Microsoft in Q4 2021, an estimated $1.08B increase.
- Marshall Wace's biggest Q4 2021 reduction was Accenture, cutting an estimated $192M.
- Marshall Wace fully exited Sabre in Q4 2021, selling an estimated $44.1M.
- Marshall Wace's ten largest holdings make up 16% of its $54.2B portfolio in Q4 2021.
- Marshall Wace opened 1,635 new positions and closed 782 in Q4 2021.
- Marshall Wace's portfolio value rose 125% quarter-over-quarter to $54.2B.
Based on Marshall Wace's 13F filing for Q4 2021, filed 14 Feb 2022.